タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	知っていますか? 抗血栓療法のための, 消化管出血の知識
出版社	メディカルサイエンス社
発行日	2014-03-25
著者	山下武志(著) 岡本真(著)
ISBN	9784903843520
ページ数	144
版刷巻号	第1版3刷
分野	臨床医学：内科消化器一般
閲覧制限	未契約

意外と多い、抗血栓療法中の消化管出血。出血してから慌てるよりも、その成り立ちや処置についてまずはきちんと知っておきませんか？心房細動診療のオピニオンリーダーと、消化器内視鏡の名手がタッグを組んでお届けする、ありそうでなかった消化管出血の本。

目次

表紙
閲覧
もくじ
P.2閲覧
はじめに
P.4閲覧
1. 抗血栓療法をするとき…必要なバランス感覚
P.7閲覧
- コラム : 抗血栓薬服用中のイベントと死亡率の関係
2. 見過ごされた大出血
P.12閲覧
- コラム : 脳卒中と大出血のコスト
3. 消化管出血が患者の将来を予測する?
P.21閲覧
4. ヒトは自然に出血し、知らぬうちに止血している
P.26閲覧
- コラム : 頭蓋内出血の痕跡? Microbleeds
5. 上部消化管出血の内訳と死亡率
P.31閲覧
6. 上部消化管出血のキーワード3つ : NSAIDs、アスピリン、H.pylori菌
P.35閲覧
7. NSAIDsはこれほど危険
P.45閲覧
8. 抗血栓薬の服用で、上部消化管出血の臨床像は変化するのだろうか?
P.50閲覧
9. 新規経口抗凝固薬と消化管出血 : まだ謎の残る分野
P.54閲覧
- コラム : ダビガトランの消化器症状と消化管出血
10. 増加し続ける抗血小板薬と抗凝固薬の併用率
P.58閲覧
11. 上部消化管出血への備え : PPIと除菌療法
P.62閲覧
- コラム : PPIが歴史を変えた!
- コラム : 除菌療法中の抗凝固療法
- コラム : PPIに関する不安材料
12. 上部消化管出血 : 生じたらどうする?
P.73閲覧
13. その評価は正当? : 下部消化管出血
P.80閲覧
14. 大腸憩室が増加している!
P.85閲覧
- コラム : 食事で大腸憩室の頻度が変わる?
15. 大腸疾患と年齢・人種差
P.92閲覧
16. 下部消化管出血の危険因子
P.95閲覧
17. 下部消化管出血 : 生じたらどうする?
P.99閲覧
18. 消化管出血で抗血栓療法を中止したら…
P.107閲覧
19. 内視鏡検査を行う消化器内科医の気持ち
P.111閲覧
おわりに
P.121閲覧
Key Message集
P.122閲覧
索引
P.134閲覧
文献
P.136閲覧
著者略歴
閲覧
奥付
閲覧

参考文献

文献

P.136 掲載の参考文献

1) Eikelboom JW, et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013 Sep 3 ; 62(10) : 900-8.

2) Pilote L, et al. Temporal trends in medication use and outcomes in atrial fibrillation. Can J Cardiol. 2013 Oct ; 29(10) : 1241-8.
pubmed

3) Toyoda K, et al ; Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke. 2008 Jun ; 39(6) : 1740-5.

4) Inoue H, et al ; J-RHYTHM Registry Investigators. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation : results of the J-RHYTHM Registry. Circ J. 2013 ; 77(9) : 2264-70.

5) Jasuja GK, et al. Identifying major hemorrhage with automated data : results of the Veterans Affairs study to improve anticoagulation (VARIA). Thromb Res. 2013 Jan ; 131(1) : 31-6.
pubmed

6) Connolly SJ, et al ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17 ; 361(12) : 1139-51.

7) Patel MR, et al ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8 ; 365(10) : 883-91.

8) Granger CB, et al ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15 ; 365(11) : 981-92.

9) Gomes T, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ. 2013 Feb 5 ; 185(2) : E121-7.
pubmed

10) Naccarelli GV, et al. Rates and implications for hospitalization of patients >= 65 years of age with atrial fibrillation / flutter. Am J Cardiol. 2012 Feb 15 ; 109(4) : 543-9.

11) Piccini JP, et al. Clinical course of atrial fibrillation in older adults : the importance of cardiovascular events beyond stroke. Eur Heart J. 2014 Jan ; 35(4) : 250-6.
pubmed

12) Mercaldi CJ, et al. Long-term costs of ischemic stroke and major beeding events among medicare patients with nonvalvular atrial fibrillation. Cardiol Res Pract. 2012 ; 2012 : 645469.

13) Nikolsky E, et al. Gastrointestinal bleeding in patients with acute coronary syndromes : incidence, predictors, and clinical implications : analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009 Sep 29 ; 54(14) : 1293-302.

14) Guerrouij M, et al. The clinical impact of bleeding during oral anticoagulant therapy : assessment of morbidity, mortality and post-bleed anticoagulant management. J Thromb Thrombolysis. 2011 May ; 31(4) : 419-23.
pubmed

15) Laine L, et al. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012 Aug ; 107(8) : 1190-5.
pubmed

16) Lau JY, et al. Systematic review of the epidemiology of complicated peptic ulcer disease : incidence, recurrence, risk factors and mortality. Digestion. 2011 ;84(2) :102-13.
pubmed

17) Rockall TA, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995 Jul 22 ; 311(6999) : 222-6.

18) Targownik LE, Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding : 1993-2003. Clin Gastroenterol Hepatol. 2006 Dec ; 4(12) : 1459-66.
pubmed

19) Jorgensen PW, et al. Antiagregation and anticoagulation, relationship with upper gastrointestinal bleeding. Rev Esp Enferm Dig. 2011 Jul ; 103(7) : 360-5.
pubmed

20) 木村明裕, 岩本俊彦. 高齢者における急性消化管出血とその問題点. 日老医誌. 2009 ; 46 : 250-8.

21) Tariq SH, Mekhjian G. Gastrointestinal bleeding in older adults. Clin Geriatr Med. 2007 Nov ; 23(4) : 769-84.
pubmed

22) Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding / perforation : an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000 Jul 24 ; 160(14) : 2093-9.

23) Yeomans ND, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005 Nov 1 ; 22(9) : 795-801.
pubmed

24) Lanas A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006 Dec ; 55(12) : 1731-8.
pubmed

25) Leong RW. Differences in peptic ulcer between the East and the West. Gastroenterol Clin North Am. 2009 Jun ; 38(2) : 363-79.

26) Fujisawa T, et al. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol. 1999 Aug ; 94(8) : 2094-9.
pubmed

27) Huang JQ, et al. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease : a meta-analysis. Lancet. 2002 Jan 5 ; 359(9300) : 14-22.

28) Bakkevold KE. Time trends in incidence of peptic ulcer bleeding and associated risk factors in Norway 1985-2008. Clin Exp Gastroenterol. 2010 ; 3 : 71-7.
pubmed

29) Sokic-Milutinovic A, et al. Role of Helicobacter pylori infection and use of NSAIDs in the etiopathogenesis of upper gastrointestinal bleeding. Acta Chir Iugosl. 2007 ; 54(1) : 51-62.
pubmed

30) Gisbert JP, et al. Helicobacter pylori and bleeding duodenal ulcer : prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 2001 Jul ; 36(7) : 717-24.
pubmed

31) Ootani H, et al. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol. 2006 Jan ; 41(1) : 41-6.
pubmed

32) Nakayama M, et al. Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy. J Gastroenterol. 2009 ; 44(9) : 912-8.
pubmed

33) Hunt RH, Bazzoli F. Review article : should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther. 2004 Feb ; 19 Suppl 1 : 9-16.

34) Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999 Apr ; 56 : 18-24.
pubmed

35) Loperfido S, et al. Changing trends in acute upper-GI bleeding : a population-based study. Gastrointest Endosc. 2009 Aug ;70(2) :212-24.
pubmed

36) Schjerning Olsen AM, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction : a nationwide cohort study. Circulation. 2011 May 24 ; 123(20) : 2226-35.

37) Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002 ; 69 Suppl 1 : SI53-8.

38) Blackshear JL, et al. Renal complications of nonsteroidal antiinflammatory drugs : identification and monitoring of those at risk. Semin Arthritis Rheum. 1985 Feb ; 14(3) : 163-75.
pubmed

39) Risser A, et al. NSAID prescribing precautions. Am Fam Physician. 2009 Dec 15 ; 80(12) : 1371-8.

40) 岩本純一, 溝上裕士. 低用量アスピリンによる胃粘膜障害の実態. Helicobacter Research. 2009 ; 13 : 98-104.

41) 石川茂直, ほか. 低用量アスピリンによる重篤な胃・十二指腸障害の特徴と予防. 消化器科. 2008 ; 47 : 471-8.

42) Thomopoulos KC, et al. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy : endoscopic findings, clinical management and outcome. World J Gastroenterol. 2005 Mar 7 ; 11(9) : 1365-8.
pubmed

43) Hori M, et al ; RE-LY Investigators. Dabigatran versus warfarin : effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013 Jul ; 44(7) : 1891-6.
pubmed

44) Supplement to : Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 ; 365 : 883-91. DOI : 10.1056/NEJMoa1009638.

45) Hori M, et al ; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study -. Circ J. 2012 ; 76(9) : 2104-11.

46) Bytzer P, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013 Mar ; 11(3) : 246-52.
pubmed

47) Atarashi H, et al. J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation : a report from the J-RHYTHM Registry. Circ J. 2011 ; 75(6) : 1328-33.

48) Hallas J, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding : population based case-control study. BMJ. 2006 Oct 7 ; 333(7571) : 726.
pubmed

49) Hansen ML, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010 Sep 13 ;170(16) :1433-41.
pubmed

50) Sugano K, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy : results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2011 Jun ; 46(6) : 724-35.

51) Chan FK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001 Mar 29 ; 344(13) : 967-73.

52) Ng FH, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010 Jan ; 138(1) : 82-8.
pubmed

53) Chan FK, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005 Jan 20 ; 352(3) : 238-44.
pubmed

54) Hsu PI, et al. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011 Mar ; 140(3) : 791-8.
pubmed

55) Taha AS, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS) : a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009 Jul 11 ; 374(9684) : 119-25.

56) Yeomans N, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008 Oct ; 103(10) : 2465-73.
pubmed

57) Nishino M, et al. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori - negative healthy volunteers. J Clin Pharmacol. 2011 Jul ; 51(7) : 1079-86.
pubmed

58) Lanas A, et al ; Investigators of the Asociacion Espanola de Gastroenterologia (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007 Mar ; 102(3) : 507-15.

59) Bhatt DL, et al ; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11 ; 363(20) : 1909-17.

60) Hungin AP, et al. Co-prescription of H2 receptor blockers and proton pump inhibitors with warfarin in general practice. Postgrad Med J. 1999 Dec ; 75(890) : 721-2.
pubmed

61) Hermansson M, et al. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. BMC Gastroenterol. 2009 Apr 20 ; 9 : 25.

62) Heidelbaugh JJ, et al. Overutilization of protonpump inhibitors : what the clinician needs to know. Therap Adv Gastroenterol. 2012 Jul ; 5(4) :219-32.
pubmed

63) Casado Arroyo R, et al. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy : long-term follow-up of a cohort of patients commonly using PPI cotherapy. Heart. 2012 May ; 98(9) : 718-23.
pubmed

64) Strate LL. Lower GI bleeding : epidemiology and diagnosis. Gastroenterol Clin North Am. 2005 Dec ; 34(4) : 643-64.
pubmed

65) Zuckerman GR, Prakash C. Acute lower intestinal bleeding. Part II : etiology, therapy, and outcomes. Gastrointest Endosc. 1999 Feb ; 49(2) : 228-38.
pubmed

66) Stollman N, Raskin JB. Diverticular disease of the colon. Lancet. 2004 Feb 21 ; 363(9409) : 631-9.

67) Meyers MA, et al. Pathogenesis of massively bleeding colonic diverticulosis : new observations. Am J Roentgenol. 1976 Dec ; 127(6) : 901-8.

68) Warner E, et al. Fourteen-year study of hospital admissions for diverticular disease in Ontario. Can J Gastroenterol. 2007 Feb ; 21(2) : 97-9.
pubmed

69) Jun S, Stollman N. Epidemiology of diverticular disease. Best Pract Res Clin Gastroenterol. 2002 Aug ; 16(4) : 529-42.
pubmed

70) Colecchia A, et al. Diverticular disease of the colon : new perspectives in symptom development and treatment. World J Gastroenterol. 2003 Jul ; 9(7) : 1385-9.
pubmed

71) Poncet G, et al. Natural history of acute colonic diverticular bleeding : a prospective study in 133 consecutive patients. Aliment Pharmacol Ther. 2010 Aug ; 32(3) : 466-71.
pubmed

72) Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage : a population-based study. Am J Gastroenterol. 1997 Mar ; 92(3) : 419-24.
pubmed

73) Painter NS, Burkitt DP. Diverticular disease of the colon : a deficiency disease of Western civilization. Br Med J. 1971 May 22 ; 2(5759) : 450-4.

74) Ferlitsch M, et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA. 2011 Sep 28 ; 306(12) : 1352-8.

75) Lieberman DA, et al. Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA. 2008 Sep 24 ; 300(12) : 1417-22.

76) Wu X, et al ; Comparative Analysis of Incidence Rates Subcommittee, Data Evaluation and Publication Committee, North American Association of Central Cancer Registries. Subsite-specific colorectal cancer incidence rates and stage distributions among Asians and Pacific Islanders in the United States, 1995 to 1999. Cancer Epidemiol Biomarkers Prev. 2004 Jul ; 13(7) : 1215-22.
pubmed

77) Yamada A, et al. Assessment of the risk factors for colonic diverticular hemorrhage. Dis Colon Rectum. 2008 Jan ; 51(1) : 116-20.
pubmed

78) Niikura R, et al. Hypertension and concomitant arteriosclerotic diseases are risk factors for colonic diverticular bleeding : a case-control study. Int J Colorectal Dis. 2012 Sep ; 27(9) : 1137-43.
pubmed

79) Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999 Jul ; 117(1) : 17-25.

80) Hashash JG, et al. Gross lower gastrointestinal bleeding in patients on anticoagulant and/or antiplatelet therapy : endoscopic findings, management, and clinical outcomes. J Clin Gastroenterol. 2009 Jan ; 43(1) : 36-42.
pubmed

81) Sung JJ, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding : a randomized trial. Ann Intern Med. 2010 Jan 5 ; 152(1) : 1-9.
pubmed

82) Rodriguez LA, et al. Discontinuation of low dose aspirin and risk of myocardial infarction : casecontrol study in UK primary care. BMJ. 2011 Jul 19 ; 343 : d4094.

83) Biondi-Zoccai GG, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006 Nov ; 27(22) : 2667-74.
pubmed

84) Maulaz AB, et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005 Aug ; 62(8) : 1217-20.

85) Witt DM, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med. 2012 Oct 22 ; 172(19) : 1484-91.

86) 藤本一眞ほか : 日本消化器内視鏡学会, 日本循環器学会, 日本神経学会, 日本脳卒中学会, 日本血栓止血学会, 日本糖尿病学会. 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. Gastroenterological Endoscopy 2012 ; Jul. 54(7) : 2073-102.

はじめての方へ

個人／法人会員登録のご案内